Citius Pharma Moves Forward with Mino-Lok Phase 3 Trial
CRANFORD, N.J., Dec. 8, 2016 /PRNewswire/ -- Citius Pharmaceuticals, Inc. ("Citius") (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, provided details of its phase 3 trial for Mino-Lok, an antibiotic lock solution used to salvage infected central venous catheters (CVCs) and to treat catheter related bloodstream infections (CRBSIs). Mino-Lok is being developed as an adjunctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI) in combination with appropriate systemic antibiotic(s), to salvage infected CVCs, to preserve central venous access, and to avoid the complications and morbidities associated with catheter removal and reinsertion.
Manufacturing of the clinical trial components which consists of minocycline HCl in the first pre-mix component and a solution of disodium EDTA and ethanol in the second component have been finalized; and, the two components are being assembled for distribution to the clinical trial sites.
Clinical trial startup activities are underway and Citius is recruiting and qualifying sites for the trial. The first patient is expected to be enrolled in early 2017.
Myron Holubiak, President and CEO stated, "We have been working diligently to assure that all of the work streams are coming together at the right time to begin our registration trial in the first quarter of 2017. Mino-Lok is Citius' lead product, and we believe we will be able to show that there is an alternative to subjecting bacteremic patients to the risky CVC removal and replacement procedures. Mino-Lok may improve outcomes in these patients. We are also encouraged to see the passage of the 21st Century Cures Act by Congress last week. The Act amends the Federal Food, Drug, and Cosmetic Act to require the FDA to establish processes under which patient experience data may be considered in the risk-benefit assessment of a new drug. We strongly believe that Mino-Lok therapy improves patient experience as compared to remove and replace procedures. As was reported earlier, Mino-Lok has already received Qualified Infectious Disease Product (QIDP) designation which allows for Fast Track, Priority Review and extended market exclusivity."
In the US, approximately 7 million CVCs are used annually and nearly 500,000 of those result in CRBSIs leading to serious, life threatening infections and morbidities. Currently, the treatment for patients with a CRBSI is to treat the bacteremia with appropriate systemic antibiotic therapy, and in most cases remove the infected catheter and replace it with a new one at a new venous access site. This process of removing and replacing the catheter in seriously ill patients with CRBSIs is difficult, costly, and carries significant clinical risks. Salvaging an infected catheter in these settings would be an important clinical advance. This trial will be the largest and most definitive study to date to examine if antibiotic locks can be used to salvage infected catheters.
There are currently no approved therapies to salvage infected CVCs.
Mino-LokTM is under investigation and not approved for commercial use.
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. We focus on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches. www.citiuspharma.com
Safe Harbor
This press release may contain "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Such statements are made based on our expectations and beliefs concerning future events impacting Citius. You can identify these statements by the fact that they use words such as "will," "believe," "anticipate," "estimate," "expect," "should," and "may" and other words and terms of similar meaning or use of future dates. Forward-looking statements are based on management's current expectations and are subject to risks and uncertainties that could negatively affect our business, operating results, financial condition and stock price. Factors that could cause actual results to differ materially from those currently anticipated are: risks related to our growth strategy; risks relating to the results of research and development activities; uncertainties relating to preclinical and clinical testing; the early stage of products under development; our ability to obtain, perform under and maintain financing and strategic agreements and relationships; our ability to identify, acquire, close and integrate product candidates and companies successfully and on a timely basis; our dependence on third-party suppliers; our ability to attract, integrate, and retain key personnel; our need for substantial additional funds; government regulation; patent and intellectual property matters; competition; as well as other risks described in our SEC filings. We expressly disclaim any obligation or undertaking to release publicly any updates or revisions to any forward looking statements contained herein to reflect any change in our expectations or any changes in events, conditions or circumstances on which any such statement is based, except as required by law.
Contact:
Andrew Scott
Vice President, Corporate Development
(O) 908-967-6676 (M) 646-522-8410
ascott@citiuspharma.com
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/citius-moves-forward-with-mino-lok-phase-3-trial-300373829.html
SOURCE Citius Pharmaceuticals, Inc.
